Optos and Toku Partner to Bring AI-Powered “BioAge” to U.S. Eye Care Practices

Optos announced a new agreement with Toku to integrate Toku’s BioAge solution into Optos devices across the United States.

Toku’s BioAge technology uses artificial intelligence to estimate a patient’s biological age—a key indicator of overall systemic health—by analyzing vascular and metabolic markers visible in the retina. According to Optos, with just one pair of ultra-widefield retinal images, eye care professionals can provide patients with actionable information that extends well beyond traditional eye exams, offering a window into cardiovascular and metabolic wellness.

The collaboration enables users of Optos Daytona, Monaco, Monaco Pro, and California devices to adopt BioAge without replacing existing hardware. 

“We are delighted to offer our customers the ability to seamlessly integrate BioAge into their workflow,” said Masayuki Numako, Director & Executive Vice President, Head of Healthcare Business Division at Optos. “This collaboration allows eye care professionals to deliver greater value to their patients through a deeper understanding of overall wellness.”

“Our mission is to empower individuals with health insights that encourage proactive care and healthier lifestyles,” said Ehsan Vaghefi, CEO of Toku. “Through this agreement with Optos, we are excited to make BioAge accessible to more than 20,000 eyecare practices across the United States equipped with ultra-widefield imaging devices.”

The integrated BioAge solution will debut at Vision Expo West in Las Vegas, September 17–20, at Optos booth F9065.